Cyclopenthiazide
CAS: 742-20-1
Ref. 3D-FC146926
10mg | Discontinued | ||
25mg | Discontinued | ||
50mg | Discontinued | ||
100mg | Discontinued | ||
250mg | Discontinued |
Product Information
- 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(cyclopentylmethyl)-3,4-dihydro-, 1,1-dioxide
- 6-Chloro-3-(cyclopentylmethyl)-3,4-dihydro-7-sulfamyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
- 6-Chloro-3-cyclopentylmethyl-7-sulfamoyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide
- 6-chloro-3-(cyclopentylmethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
- 6-chloro-3-cyclopentylmethyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide
- Benesal
- Ciba 8341-Su
- Cyclomethiazide
- Cyclometiazid
- Cyclopentiazid
- See more synonyms
- NSC 107679
- Navidreks
- Navidrex
- Navidrix
- Salimed
- Salimid
- Salurilo-C
- Su 8341
- Tsiklometiazid
- Ultra-Minzil
Cyclopenthiazide is an oral hypoglycaemic agent used for the treatment of diabetes mellitus in geriatric patients. It inhibits protein synthesis by binding to the ribosomes and preventing their attachment to the mRNA. Cyclopenthiazide also has anti-infectious properties, which may be due to its inhibitory effects on basic fibroblast growth factor (bFGF). This drug has been shown to reduce potassium dichromate-induced neoplasia in mice by inhibiting protein synthesis and promoting cell death. Cyclopenthiazide is metabolized in the liver via a number of pathways, including glutathione conjugation, cytochrome P450 oxidation, or hydrolysis by esterases.
The following are some side effects associated with this drug:
Cardiac: cyclopenthiazide can cause cardiac arrhythmia or hypotension; it should not be taken by people with congestive heart failure or who have had a heart